RJFSA
LTRN icon

Raymond James Financial Services Advisors’s Lantern Pharma LTRN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,896
Closed -$50.9K – 3514
2024
Q2 		$50.9K Sell
10,896
-1,108
-9% -$6.66K ﹤0.01% 3297
2024
Q1 		$106K Buy
+12,004
New +$64.1K ﹤0.01% 3219

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Raymond James Financial Services Advisors's LTRN Position: Q3 2024 in Review

Raymond James Financial Services Advisors sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 10,896 shares — an estimated $50.9K sold.

Raymond James Financial Services Advisors first reported a position in LTRN in Q1 2024 and held it in 2 quarters. The position peaked at $106K in Q1 2024. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

  • Raymond James Financial Services Advisors reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,896 Lantern Pharma shares in Q3 2024, an estimated $50.9K.
  • Raymond James Financial Services Advisors first reported a position in Lantern Pharma in Q1 2024 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Lantern Pharma position peaked at $106K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.